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MicroRNA-466 inhibits tumor growth and bone
metastasis in prostate cancer by direct regulation of
osteogenic transcription factor RUNX2
Melissa Colden1, Altaf A Dar2, Sharanjot Saini1, Priya V Dahiya1, Varahram Shahryari1, Soichiro Yamamura1, Yuichiro Tanaka1,
Gary Stein3, Rajvir Dahiya1 and Shahana Majid*,1
MicroRNAs (miRNAs) have emerged as key players in cancer progression and metastatic initiation yet their importance in
regulating prostate cancer (PCa) metastasis to bone has begun to be appreciated. We employed multimodal strategy based on
in-house PCa clinical samples, publicly available TCGA cohorts, a panel of cell lines, in silico analyses, and a series of in vitro and
in vivo assays to investigate the role of miR-466 in PCa. Expression analyses revealed that miR-466 is under-expressed in PCa
compared to normal tissues. Reconstitution of miR-466 in metastatic PCa cell lines impaired their oncogenic functions such as cell
proliferation, migration/invasion and induced cell cycle arrest, and apoptosis compared to control miRNA. Conversely, attenuation
of miR-466 in normal prostate cells induced tumorigenic characteristics. miR-466 suppressed PCa growth and metastasis through
direct targeting of bone-related transcription factor RUNX2. Overexpression of miR-466 caused a marked downregulation of
integrated network of RUNX2 target genes such as osteopontin, osteocalcin, ANGPTs, MMP11 including Fyn, pAkt, FAK and
vimentin that are known to be involved in migration, invasion, angiogenesis, EMT and metastasis. Xenograft models indicate that
miR-466 inhibits primary orthotopic tumor growth and spontaneous metastasis to bone. Receiver operating curve and Kaplan–
Meier analyses show that miR-466 expression can discriminate between malignant and normal prostate tissues; and can predict
biochemical relapse. In conclusion, our data strongly suggests miR-466-mediated attenuation of RUNX2 as a novel therapeutic
approach to regulate PCa growth, particularly metastasis to bone. This study is the first report documenting the anti-bone
metastatic role and clinical significance of miR-466 in prostate cancer.
Cell Death and Disease (2017) 8, e2572; doi:10.1038/cddis.2017.15; published online 26 January 2017
Prostate cancer is the second most leading cause of cancer
related deaths among American men.1 According to recent
data, it is estimated that 220, 800 newly diagnosed prostate
cancer cases and 27 540 deaths will occur in 2015.1 The 5
year relative survival rate of early stage prostate cancer is
499% while that of advanced metastatic disease is only
28%.1 Metastases often occur with no prior indication of tumor
invasiveness.2 A major challenge for treatment of advanced
metastatic disease is the lack of understanding of the
molecular mechanisms underlying the propensity of prostate
cancer to metastasize to other organs, particularly the bone. A
number of transcription factors have been identified that play
key roles in promoting oncogenesis, tumor growth, metastasis
and tissue destruction.
Runt-domain containing protein RUNX2 (also called Osf2/
Cbfa1, AML-3 or Pebp2αA) is a member of the RUNX family of
genes. It is a lineage-specific transcription factor with crucial
roles in both bone biology and carcinogenesis.3–5 High levels
of RUNX2 in metastatic prostate cancer emphasize the
significance of this master skeletal transcription factor in
potentiating tumor cell progression and metastatic bone
disease.6–8 The oncogenic potential of RUNX2 was first
documented T-cell lymphoma.9,10 Since then, a number of
independent studies have reported involvement of RUNX2 at
early and late stages of tumor progression in various
cancers.6,7,11–15 RUNX2 was found to be up-regulated and a
predictor of metastasis in prostate cancer.16 Mechanistic
studies indicated that RUNX2 accelerated prostate cancer
aggressiveness through promotion of cadherin switching,
invasion toward collagen I and Akt activation.16 In addition,
attenuation of RUNX2 expression in a PC3 subline led to
increased adhesion to fibronectin.7 Various reports have
convincingly shown that the severity of prostate andmammary
cancer cell osteolysis is correlated with levels of RUNX2
expression following injection of neoplastic cells in the
medullary cavity of the tibia.7,8,14 These findings suggest that
RUNX2 can imbue neoplastic cells with the capacity to
breakdown the architecture of surrounding tissues, potentially
releasing tumor supporting factors indicating that RUNX2 may
facilitate a bone-mimetic program that helps cells adapt and
thrive in this foreign environment. RUNX2 also directly induced
genes associated with angiogenesis, invasiveness, metasta-
sis and stimulated epithelial-to-mesenchymal transition of
primary tumors.15–17 Taken together these studies provide
convincing evidence for RUNX2 as a potentially important
factor in prostate cancer development and metastasis.
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Targeting RUNX2 in prostate cancer could interrupt an
integrated network of gene expression required to maintain
tumor growth and bone metastasis. Here we report use of
miR-466 as a potentially novel avenue to regulate RUNX2 and
its downstream genes, thereby inhibiting prostate cancer
growth and bone metastasis.
MicroRNAs (miRNA) are small (20–25 nucleotides) evolu-
tionarily conserved non-coding RNAs that negatively regulate
transcript levels through sequence-dependent recognition
mechanisms.18 Over the past several years it has become
clear that alteration in the expression of miRNA genes
contribute to the pathogenesis of many human malignancies.
Carcinogenesis involves multiple genetic and epigenetic
events, yet the organizing principles underlying their choreo-
graphy are poorly understood. miRNA deregulation is an
important component of this landscape given the oncogenic
and tumor-suppressive functions of miRNAs.18 Since malig-
nant cells have dysregulated expression of miRNAs, which in
turn control or are controlled by the dysregulation of multiple
protein-coding oncogenes or tumor suppressor genes, these
miRNAs may be important for the development of miRNA-
based therapies.18 In addition miRNAs have great potential as
diagnostic and prognostic biomarkers. Owing to their tissue
specificity, miRNAs have become useful tools for defining the
origin of tumors in poorly differentiated cancers.19 With the
advent of miRNA expression profiles, significant efforts have
been made to correlate miRNA expression with tumor
prognosis.20–23 These reports even suggest that expression
profiling of miRNAs may be a more accurate method of
classifying cancer subtypes than using the expression profiles
of protein-coding genes.22,24 Various studies have established
miRNA expression patterns as potential biomarkers for
diagnosis, prognosis, personalized therapy, disease manage-
ment and clinical outcome in various cancers.25–30 To date,
28 645 miRNAs have been identified (http://www.mirbase.org)
although their role in disease pathogenesis is not well
documented.
Here for the first timewe show that miR-466 inhibits prostate
cancer bone metastasis. miR-466 is significantly under-
expressed in a panel of prostate cancer cell lines and clinical
tissues compared to normal. Restoration of miR-466 expres-
sion in highly metastatic PC3 and Du145 prostate cancer cell
lines impaired proliferation, migration, invasion and induced
cell cycle arrest and apoptosis in vitro. Importantly, miR-466
Figure 1 MiR-466 expression is downregulated in prostate cancer (a) Expression of miR-466 was analyzed by qRT-PCR in a panel of prostate cancer lines compared to a
non-malignant cell line (RWPE1). (b) Expression of miR-466 in a patient cohort (n= 96; 48 pairs) of matched LCM tissue samples from in-house VAMC cohort. (c) Confirmation
of miR-466 expression in an independent validation cohort of prostate adenocarcinoma (n= 56) publicly available at the TCGA data base
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has a profound inhibitory effect on prostate cancer growth and
bone metastasis in vivo. We further demonstrated that
miR-466 partially exerted these effects by directly targeting
runt-related RUNX2, a master osteogenic transcription factor
and attenuated its downstream target genes that are known to
mediate prostate cancer bonemetastasis. In addition, our data
indicates that miR-466 is potentially a clinically significant
prostate cancer biomarker.
Results
miR-466 expression is significantly downregulated in
prostate cancer. In a previous study,31 we performed
preliminary screening to identify differentially expressed
miRNAs in prostate cancer cell lines compared to a non-
malignant cell line. A set of miRNAs, miR-466, -205, -203,
-23b and -34b were found to be significantly downregulated in
prostate cancer cells compared to a non-malignant cell line.
We validated miR-466 data by miRNA-quantitative real-time
PCR (miR qRT-PCR) analysis. The results confirmed that
miR-466 was significantly downregulated in a panel of
prostate cancer cell lines compared to normal RWPE1 cells
(Figure 1a). Further, miR-466 expression was analyzed in an
experimental cohort of laser-captured micro-dissected (LCM)
matched patient samples from the San Francisco VA Medical
Center (VAMC cohort) and attenuation of miR-466 expres-
sion was confirmed (Figure 1b). The expression of miR-466
was downregulated in 85% of PCa tissue samples compared
to matched normal tissues (Po0.0001; Figure 1b). Suppres-
sion of miR-466 in the experimental cohort was validated by
analyzing an independent cohort of prostate adenocarcinoma
available publicly at The Cancer Genome Atlas (TCGA) data
base (Po0.001; Figure 1c). These results indicate a putative
tumor suppressor role for miR-466 in prostate cancer. We
reason that tumor suppressor miRNAs would be expressed
at low levels in tumors but more highly expressed in normal
tissues. MiR-466 fulfills this criterion, exhibiting high
expression in normal prostate tissues and a non-malignant
cell line and low or silenced expression in prostate cancer
samples and cell lines.
Figure 2 Functional significance of miR-466 in prostate cancer. (a) Expression of miR-466 after transient transfection of miR-466 mimic in PC3 cells compared to a
scrambled negative control miRNA (Neg-miR). (b and c) PC3 and Du145 cells expressing miR-466 were subjected to transwell assay to evaluate chemotactic migration (b) and
invasion (c). Assays were performed after 18 h of transient transfection of miR-466 in PC3 and Du145 cells. Data are represented as the mean± s.d. Images are those of mock,
neg-miR and miR-466 transfected groups. (d–f) Immunoblot assay of endogenous levels of proteins involved in proliferation, migration, invasion and EMT in PC3 and Du145 cells
transfected with miR-466 or neg-miR. GAPDH was used as an internal control
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miR-466 overexpression suppresses cell proliferation,
migration, invasion, reverses epithelial-to-mesenchymal-
transition (EMT) and induces cell cycle arrest and
apoptosis in prostate cancer. To ascertain the functional
significance of miR-466 overexpression in prostate cancer
cells, we performed migration, invasion, proliferation, cell
cycle and apoptosis assays. Transient transfection of
miR-466 mimic (50 nM for 72 h; Figure 2a) caused a
significant decrease in migration (Figure 2b) and invasion
(Figure 2c) of PC3 and Du145 prostate cancer cells. We also
examined the effect of overexpression of miR-466 on
markers involved in migration, invasion and EMT. Ectopic
expression of miR-466 significantly decreased Fyn, Fak and
pAkt protein levels that are implicated in migration and
invasion of human prostate cancer (Figures 2d–f). In addition,
a decrease in Vimentin (mesenchymal marker) and an
increase in E-cadherin (epithelial marker) was observed in
miR-466 transfected cells compared to cont-miR transf-
ection (Figures 2e and f). EMT is involved in epithelial-
derived tumors causing them to become invasive and
metastatic. These results show that miR-466 suppr-
essed EMT markers along with other migratory/invasive
genes attesting to the metastatic suppressor role of miR-466
in vitro.
Unregulated cell proliferation and survival are common
features of cancer cells that favor metastatic dissemination.
Reconstitution of miR-466 in metastatic PC3 and Du145
prostate cancer cells inhibited cell proliferation (Figures 3a
and b), induced G0/G1 cell cycle arrest (Figures 3c and d) and
apoptosis (Figures 3e and f) compared to control miRNA.
These results confirm the tumor suppressor phenotypic
effects of miR-466 overexpression in human prostate
cancer cells.
miR-466 inhibits primary tumor growth and bone metas-
tasis in vivo. To recapitulate the in vitro findings and to
examine the role of miR-466 in tumorigenesis in vivo,
bioluminescent PC3M-Luc-C6 cells (1 × 106 cells) constitu-
tively expressing cont-miR or miR-466 were orthotopically
implanted into the posterior prostatic lobe of athymic nude
mice (Figure 4a). Mice were bioimaged immediately to check
equal distribution of cells as indicated by the luciferase signal
intensity at day 0 in both groups. Regular monitoring of mice
with the IVIS imaging system was performed on a weekly
basis. miR-466 significantly reduced the primary tumor size
as determined by bioluminescence imaging over the course
of the experiment (Figures 4a and b) compared to control.
Mice in both groups survived until the end of the experiment.
Figure 3 Reconstitution of miR-466 inhibits cell proliferation and induces cell cycle arrest and apoptosis in prostate cancer. (a and b) Proliferation of PC3 and Du145 cells
ectopically expressing miR-466 or neg-miR was determined by MTS assay. (c and d) FACS cell cycle and (e and f) apoptosis analyses of PC3 and Du145 cells expressing
miR-466 compared to negative control miRNA. Values are mean of three independent experiments± S.D. and the quadrants are representatives of the experiment
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In view of the robust inhibitory effect of miR-466 on migration
and invasion of prostate cancer cells in vitro, we reasoned
that it may also inhibit metastasis in vivo. Indeed, miR-466
suppressed spontaneous metastasis to bone 7 weeks after
intracardiac injection compared to controls (Figures 4c
and d). Control cells grew aggressively and metastatic
lesions were observed in the knee, jaw and ribs whereas
miR-466 drastically inhibited bone metastasis. Mice were
monitored for survival and all eight control mice either died or
had to be killed because of tumor burden by the 7th week. In
the miR-466 mouse group 7 of 8 mice survived until the 20th
week when the experiment was terminated. We performed
Kaplan–Meier survival analysis and the results indicated that
low-miR-466 expression strongly (Po0.0001) correlates with
poor overall survival compared to the high miR-466 expres-
sion group (HR= 17; 95% CI= 5–50; Figure 4e). These
results confirm that miR-466 functions as a significant tumor
and bone metastasis suppressor gene in prostate cancer.
miR-466 directly represses osteogenic transcription
factor RUNX2. We next sought to determine the underlying
molecular mechanism of miR-466 mediated inhibition of
tumor growth and bone metastasis. Thus, we utilized in silico
computational algorithms to identify miR-466 target genes
involved in these processes. Two different miRNA databases
(microrna.org; mirdb.org) identified three complimentary
miR-466 binding sites in the 3′UTR of RUNX2 (Figure 5a).
Ectopic expression of miR-466 significantly attenuated
RUNX2 protein levels, suggesting a functional role in
controlling protein translation (Figure 5b). Luciferase reporter
assays validated that miR-466 directly targets the wild-type 3′
UTR of RUNX2 as co-transfection of the miR-466 along with
wild-type RUNX2 3′UTR significantly repressed relative
luciferase activity (Figure 5c) in PC3 and Du145 cells. No
effect was observed with cont-miR or miR-466 cells
transfected with a non-specific 3′UTR control vector
(Figure 5c).
Figure 4 MiR-466 inhibits primary tumor growth and bone metastasis in vivo. (a and b) Primary tumor growth in an in vivo intraprostatic xenograft model was determined by
quantifying the bioluminescent signal after orthotopically transplanting bone metastatic PC3 cells stably expressing miR-466. (c and d) miR-466 significantly inhibited
spontaneous metastases to bone indicated by the bioimaging of mice after intracardiac implantation of constitutively miR-466 expressing PC3 cells. (b and d) Representative
images of mice from each group of in vivomodels. (d8) Bioluminescent signal in harvested leg and skull of control and miR-466 group. (e) Kaplan–Meier survival curve based on
intracardiac spontaneous metastatic model. In a and b data are represented as mean± S.E.M. of each group
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miR-466 suppresses multiple RUNX2 target genes
related to tumor growth and bone metastasis. Next we
determined the effect of miR-466 mediated RUNX2 suppres-
sion on downstream pathway genes. As a consequence of
inhibited RNUX2 expression, several RUNX2 target genes
associated with angiogenesis, invasiveness and metastasis
including ANGPT1, ANGPT4, Osteopontin (Spp1), Osteocal-
cin (OC) and MMP11, were downregulated by miR-466
compared with control cells (Figures 5d–h). These results
further support our hypothesis that the effect of miR-466 in
prostate tumorigenesis and metastasis is mediated through
inhibition of RUNX2 and its metastasis-promoting down-
stream target genes.
Knockdown of endogenous miR-466 in non-malignant
RWPE1 cells induces pro-cancerous attributes. To
assess the biological significance of miR-466 in prostate
cancer; we performed parallel experiments using non-
cancerous RWPE1 cells. miR-466 was knocked down in
RWPE1 cells by transient transfection of anti-miR-466 (miR-
-466 inhibitor; 50 nM) along with a negative-anti-miRNA-
control (control; Figure 6a). RWPE1 cells transfected with
anti-miR-466 showed a considerable increase in cell pro-
liferation (Figure 6b), migration and invasion (Figures 6c–f)
compared to controls. These data provide evidence that
suppression of miR-466 caused RWPE1 cells to have
cancer-like characteristics further attesting to its tumor
suppressor role in prostate cancer.
Clinical significance of miR-466 in prostate cancer.
Statistical analyses were performed by combining the in-
house VAMC cohort and prostate adenocarcinoma sample
cohorts available at TCGA data portal. Clinical demographics
of the study cohort are summarized in Supplementary
Table 1. VAMC samples were dichotomized based on the
relative expression of miR-466 and grouped into low (o1-fold
relative to matched normal) and high (41-fold) miR-466
expression groups; whereas TCGA samples were grouped
as low (omean expression) and high (4mean expression)
groups. Correlation of miR-466 expression was assessed
with clinic-pathological variables such as Gleason grade,
pathological stage (pT) and biochemical recurrence
(Figure 7a). The time of recurrence was defined as the first
postoperative PSA value40.1 ng/ml after surgery. Thirty-four
patients experienced a biochemical relapse according to this
criterion. A significant correlation was observed between
miR-466 expression with clinical variables. In higher patho-
logical grade samples (pT3-T4), decreased miR-466 expres-
sion was observed in 89% cases compared to 11% of cases
that had high miR-466 expression (Po0.0001). In lower
pathological stage (pT2) cases, decreased expression of
miR-466 was observed in 75% of cases while 25% of cases
showed high miR-466 expression (Po0.0001; Figure 7a). To
analyze the correlation with Gleason score, we divided the
samples into lowo7, medium 7 and high47 Gleason score
groups. In the low group (o7), lower expression of miR-466
was found in 76% cases, whereas 24% cases had high
Figure 5 MiR-466 directly regulates osteogenic transcription factor RUNX2 and attenuates RUNX2 target genes related to tumor growth and bone metastasis. (a) Schematic
representation of miR-466 complimentary binding sites in the RUNX2 3′UTR by in silico computational algorithms (microrna.org and mirdb.org). (b) Endogenous RUNX2 protein
was detected in miR-466 and neg-miR (control) tranfected PC3 and Du145 cells by immunoblot analysis. GAPDH was used as a loading control. (c) Luciferase-RUNX2 reporter
assays. miR-466 and neg-miR were transfected into PC3 and Du145 cells co-transfected with RUNX2 3′UTR or control non-specific plasmid construct. Firefly luciferase activity
was normalized to co-transfected Renilla luciferase and presented as relative luciferase activity. Data are represented as mean±S.D. (d–h) Expression of RUNX2 target genes
including ANGPT1, ANGPT4, MMP11, osteopontin (SPP1) and osteocalcin (OC) was analyzed in miR-466 and neg-miR (control) transfected cells by qRT-PCR. Data are
represented as mean±S.D.
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miR-466 expression (Po0.0001). In the medium group (7),
83% of cases had low-miR-466 expression compared to 17%
of cases with high miR-466 expression (Po0.0001). In the
high group (47), 83% of cases had low-miR-466 expression
compared to 17% of cases with high miR-466 expression
(Po0.0001; Figure 7a). In the PSA recurrence patients,
100% of cases had decreased miR-466 expression
(Po0.0001; Figure 7a). These results reveal that
number of cases with low-miR-466 expression increases
from low Gleason grade, low pathological stage to high
Gleason grade and high pathological stage. Interestingly, all
PSA recurrence patients had low-miR-466 expression sug-
gesting that miR-466 has clinical significance in prostate
cancer.
Receiver operating curve (ROC) analyses were performed
to evaluate the ability of miR-466 expression to discriminate
between normal and tumor tissues. An area under the ROC
curve (AUC) of 0.915 (Po0.0001; 95% CI= 0.858–0.954;
Figure 7b) was obtained suggesting that miR-466 expre-
ssion can discriminate between malignant and non-malignant
tissues and can be used as a diagnostic marker for PCa. As
100% of patients with biochemical relapse showed
low-miR-466 expression, we performed Kaplan–Meier
analysis to determine the ability of miR-466 to predict patient
recurrence-free survival. Indeed, high miR-466 expr-
ession was predictive of better recurrence-free patient
survival (P=0.02) compared to low-miR-466 expression
(Figure 7c). Collectively, these results suggest that
miR-466 has potential to be a diagnostic and prognostic
marker for predicting prostate cancer biochemical recurrence
though addition of more samples may strengthen these
results.
Figure 6 Knockdown of endogenous miR-466 in non-malignant RWPE1 cells induces pro-cancerous attributes. (a) Expression of miR-466 72 h post transfection of miR-466
inhibitor (anti-miR-466) or anti-control inhibitor (control) in RWPE1 cells. (b) Proliferation of RWPE1 transfected with anti-miR-466 or control analyzed by MTS assay. (c–f)
Suppression of miR-466 in RWPE1 cells induces tumorigenic attributes in these non-malignant cells as indicated by chemotactic transwell migration (c and d) and invasion
(e and f) assays. Data is represented as mean± S.D. Images are representatives from each group
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Discussion
Bone metastases are a major problem in the evolution of
prostate cancer. Considerable effort has been devoted to map
the requirements of bone lesions in prostate tumors.32,33
Experimental evidence has demonstrated that RUNX2, a
transcription factor essential for osteogenesis, is a key
regulator of bone metastasis that becomes highly activated
in prostate cancer cells that metastasize to bone.34,35 RUNX2
has been found to be associated with the osteomimetic
properties of bone metastatic prostate cancer cells via
transcription of genes implicated in osteoblastic lesions
including osteocalcin, osteopontin, VEGF and matrix metallo-
proteins (MMPs) and so on.34,35 Thus, therapeutic targeting of
RUNX2 may interrupt an integrated network of gene expres-
sion that trigger bone metastases and thus deregulate cell
survival and migration pathways of invading prostate cancer
cells. However, at present transcription factors such as
RUNX2 are not considered to be drug targets.33 Here, we
show that miR-466-mediated attenuation of RUNX2 may be a
novel therapeutic approach to regulate tumor growth and bone
metastasis in prostate cancer. Indeed, reconstitution of
miR-466 in metastatic prostate cancer cells significantly
attenuated RUNX2 protein levels, suggesting a functional role
of miR-466 in controlling RUNX2 protein translation.
miRNAs have emerged as key players in cancer progres-
sion and metastatic initiation yet the importance of miRNAs in
regulating prostate cancer bone metastasis has just begun to
be appreciated.36 In this study, we have identified miR-466 as
a suppressor of prostate cancer growth and metastasis
through direct targeting of the bone-related transcription factor
RUNX2, which is difficult to target by conventional pharmaco-
logic approaches.33,37 Our in vivo xenograft studies provide
evidence that miR-466 can inhibit primary orthotopic tumor
growth and spontaneous metastasis to bone. Expression
analyses based on our in-house VAMC patient cohort or the
publicly available TCGA data cohort revealed that miR-466 is
under-expressed in prostate cancer compared to normal
tissues. Conversely RUNX2 has been detected in human
prostate cancer tissues but not in normal prostate.6,34 In this
study, we have identified a tumor suppressor role for miR-466
in prostate cancer. Reconstitution of miR-466 in PC3 and
Du145 metastatic prostate cancer cell lines inhibited in vitro
oncogenic properties such as cell proliferation, migration and
invasion compared to controls along with induction of G0/G1
cell cycle arrest and apoptosis in both cancer cell lines.
MiRNAs control a wide range of biological functions and may
act as tumor suppressors or oncogenes.22 Alteration of their
expression plays a critical role in tumorigenesis and cancer
progression.21,38 Our study corroborates other reports that
show miRNAs are linked to the biologic activities of RUNX2 in
different cancer types.37 Recent studies have demonstrated
the potential of miRNAs in the intervention of breast cancer
progression, metastatic bone disease and other bone
pathologies.37,39 Interestingly, our study shows that the role
of miR-466 in the control of prostate cancer progression and
Figure 7 MiR-466 is a potential novel biomarker for prostate cancer. (a) χ2 test showing correlation of clinicopathological characteristics with miR-466 expression. (b) ROC
curve analysis showing performance of miR-466 expression to discriminate between malignant and non-malignant prostate tissue samples. (c) Kaplan–Meier analysis for
recurrence-free survival based on miR-466 expression. Note: different sample numbers in statistical analysis is because not all clinical information was available for all the
samples
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metastasis may be partially attributed to decreased cancer cell
proliferation, cell cycle arrest and induced apoptosis, which
features the beneficial effects of the miR-466 in regulating
prostate cancer progression. However, our study highlights a
direct role for miR-466 in reducing the bone metastatic
potential of prostate cancer cells. This is evidenced by the
fact that reconstitution of miR-466 caused a marked
downregulation of RUNX2 target genes such as osteopontin,
osteocalcin, ANGPT1, ANGPT4, MMP11 including Fyn,
pAkt, FAK and vimentin that are involved in migration,
invasion, angiogenesis, EMTand metastasis.15–17,34,35 Thus,
miR-466 orchestrates the functional activities of RUNX2 by its
convergent action on RUNX2 and its downstream target
gene network to control prostate cancer bone metastasis.
Furthermore, our study also defines the biological rele-
vance of miR-466 in prostate cancer as indicated by
induction of pro-cancerous characteristics in non-malignant
RWPE1 cells after inhibition of endogenous expression of
miR-466. Thus, our data strongly suggests a miR-466
mediated attenuation of RUNX2 may be a novel approach
to prevent bone metastatic disease in prostate cancer
(Figure 8).
miRNAs have great potential as diagnostic and prognostic
biomarkers.20–30 Owing to their tissue specificity, miRNAs
have become useful tools for defining the origin of tumors in
poorly differentiated cancers19 and these reports even
suggest that the expression profiling of miRNAs may be a
more accurate method of classifying cancer subtype than
using the expression profiles of protein-coding genes.22,24 In
this study, we found that miR-466 expression can significantly
(Po0.0001) distinguish malignant from normal tissues indi-
cating the powerful diagnostic potential of miR-466 in prostate
cancer. In addition, miR-466 expression was predictive of
recurrence-free survival (Po0.02) such that patients with
higher miR-466 expression levels had better recurrence-free
survival. Correlation analyses showed that low-miR-466
expression positively correlated with high pathological T
(P= 0.0001), Gleason grade (Po0.001) and PSA failure
(Po0.0001). Therefore, our data reveals the clinical signifi-
cance of miR-466 in prostate cancer, although it would benefit
from a larger sample cohort.
In conclusion, for the first time we provide evidence that: (i)
miR-466 is an under-expressed metastasis suppressor
miRNA in PCa; (ii) miR-466 is biologically relevant and has
biomarker potential in PCa; (iii) miR-466 directly regulates
RUNX2, a key regulator of bone metastasis; (iv) miR-466
overexpression interrupts RUNX2 integrated network of genes
required to maintain PCa growth and bone metastasis.
RUNX2, a key transcription factor, is of pivotal significance in
the pathogenesis and progression of PCa bone metastases.
Therefore, restoration of miR-466 to regulate an integrated
network of RUNX2 and its target genes may represent a
promising approach to suppress prostate cancer bone
metastases.
Materials and Methods
Cell culture, plasmids and probes/primers. Human prostate cancer
cell lines PC3, Du145, LNCaP, MDaPCa2b and a non-malignant cell line (RWPE1)
were obtained from the American Type Culture Collection (ATCC; Manassas, VA,
USA) and grown according to ATCC protocol. These human-derived cell lines were
authenticated by DNA short-tandem repeat analysis by ATCC. The experiments with
cell lines were performed within 6 months of their procurement/resuscitation.
Plasmids pEZX-MT01 miRNA 3′UTR target expression clones for RUNX2 and
miRNA Target clone control vector for pEZX-MT01 were purchased from
GeneCopoeia (Rockville, MD, USA). TaqMan probes including mimics, inhibitors
and negative controls for hsa-miR-466 (miR-466) were purchased from Applied
Biosystems (Foster City, CA, USA).
Tissue samples, LCM, qRT-PCR and validation of expression in
an independent TCGA data cohort. Tissue samples from radical
prostectomy (n= 96; 48 pairs) were obtained from the Veterans Affairs Medical
Center, San Francisco, CA, USA. A board certified pathologist identified the cancer
and normal regions on H&E stained prostate cancer tissue slides. LCM was
performed by using AutoPix System (Arcturus) and Arcturus CapSure Macro
LCM Caps (Applied Biosystems) following the manufacturer’s instructions to isolate
pure epithelial cells from normal and cancer areas of prostate tissues. Total RNA
was extracted from micro-dissected FFPE tissues or cultured cells using a
miRNeasy FFPE Kit (Qiagen, Valencia, CA, USA) or RNeasy mini kit (Qiagen),
respectively, following the manufacturer’s instructions. Total RNA was assayed for
mature miRNAs using the TaqMan MicroRNA Assays in accordance with the
manufacturer's instructions (Applied Biosystems). All RT reactions were run in a
7500 Fast Real Time PCR System (Applied Biosystems). Relative expression was
calculated using comparative Ct. Expression of miR-466 was also validated by
analyzing an independent prostate adenocarcinoma cohort publicly
available at TCGA data portal now available as genomic data commons data
portal (https://gdc-portal.nci.nih.gov/).
Cell viability, migration, invasion, cell cycle and apoptosis
assays. Cell viability was determined at 24, 48 and 72 h by using the
CellTiter 96 AQueous One Solution Cell Proliferation Assay kit (Promega, Madison,
WI, USA) according to the manufacturer’s protocol. BioCoat control and Matrigel
invasion chambers (BD Biosciences) and Cytoselect 24-well cell migration and
invasion assay kits (Cell Biolabs, Inc., San Diego, CA, USA) were used for migration
and invasion assays according to manufacturer’s protocols. Fluorescence activated
cell sorting (FACS) analysis was done 72 h post-transfection. The cells were
harvested, washed with cold PBS, and resuspended in the nuclear stain DAPI for
cell cycle analysis or stained with the 7-AAD and Annexin-V-FITC using ANNEXIN
V-FITC/7-AAD KIT (BD Biosciences) for apoptosis analysis according to the
Figure 8 Schematic representation of the role of miR-466-mediated regulation of RUNX2 in prostate cancer. Reconstitution of miR-466 in prostate cancer leads to
suppression of RUNX2 and its direct downstream target genes involved in tumor growth and bone metastasis resulting in inhibition of primary tumor growth (8-a) and bone
metastasis (8-b)
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manufacturer’s protocol. Stained cells were immediately analyzed by FACS (BD
FACSVerse; BD Biosciences).
In vivo orthotopic and intracardiac mouse models. Bioluminescent
PC3M-Luc-C6 cells (1 × 106 cells) constitutively expressing cont-miR or miR-466
were implanted into the posterior prostatic lobe or into the left cardiac ventricle of
athymic nude mice (nu/nu; 6–8 weeks old; Harlan Lab., IN, USA) followed by regular
monitoring of tumor growth and metastatic dissemination with a live animal
bioimaging system (IVIS-PerkinElmer, San Jose, CA, USA). There were ten mice in
each group for orthotopic experiment, whereas 8 mice per group for intracardiac
implantation. Bioluminescence signal intensity was quantified using the Living Image
software (IVIS-PerkinElmer). Orthotopic experiments were performed at PerkinEl-
mer research facility at San Jose, CA, USA.
Antibodies and immunoblot assays. Immunoblotting was performed as
described previously.40 In brief, protein was isolated from 70 to 80% confluent
cultured cells using RIPA Extraction Reagent (Pierce Biotechnology, Rockfield, IL,
USA) following the manufacturer’s directions. Equal amounts of protein were
resolved on 4–20% SDS polyacrylamide gels and transferred to nitrocellulose
membrane. The resulting blots were blocked with 5% non-fat dry milk and probed
with antibodies. All antibodies were obtained from Cell Signalling Technology Inc.
Denver, MA, USA except RUNX2 and GAPDH which were purchased from Santa
Cruz Biotech. Blots were visualized using Western blotting luminal reagent
(sc-2048; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA).
Luciferase assays. Complimentary miR-466 binding sites from two
different miRNA databases (microrna.org; mirdb.org) are shown in Figure 5. The
RUNX2 wild-type 3′UTR and non-specific scrambled sequence 3′UTR
control vectors were purchased from GeneCopoeia and named RUNX2-3′UTR
vector and Control-Vector, respectively. The complete sequence of vectors is
available at http://www.genecopoeia.com/. For reporter assays, cells were
transiently transfected with wild-type or control reporter plasmids and miR-466 or
negative miR (control). Firefly luciferase activities were measured using the
Dual Luciferase Assay (Promega) 18 h after transfection and the results
were normalized with Renilla luciferase. Each reporter plasmid was tra-
nsfected at least three times (on different days) and each sample was assayed
in triplicate.
Statistical analysis. Statistical analyses were performed with GraphPad
Prism 5 (La Jolla, CA, USA) and MedCalc version 10.3.2 (medcalc.org; Acacialaan,
Ostend, Belgium). All quantified data represents an average of at least triplicate
samples or as indicated. Error bars represent S.D.M. or as indicated. All tests were
performed two tailed and P-values o0.05 were considered statistically significant.
ROC were calculated to determine the potential of miR-466 to discriminate between
malignant and non-malignant samples. χ2 tests were performed to determine the
correlation between miR-466 expression and the clinicopathological characteristics.
For recurrence-free survival analysis Kaplan–Meier curves (log-rank tests) were
also performed.
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